A Survival-Related Competitive Endogenous RNA Network of Prognostic lncRNAs, miRNAs, and mRNAs in Wilms Tumor

Liu, Hengchen; Zhang, Mingzhao; Shi, Manyu; Zhang, Tingting; Zhang, Zenan; Cui, QingBo; Yang, Shaoyu; Li, ZhaoZhu

doi:10.3389/fonc.2021.608433

Cited by 8 publications

(8 citation statements)

References 41 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mutual influence of VRK1 and NOTCH pathways is related to the prognosis of laryngeal cancer ( de Miguel-Luken et al, 2016 ). VRK1 may provide new potential biomarkers for improving the prognosis and treatment of Wilms tumor (WT) patients by showing the WNT signaling pathway ( Liu et al, 2021 ). At the same time, the WNT pathway is also a crucial pathway for regulating epithelial mesenchymal EMT.…”

Section: Discussionmentioning

confidence: 99%

VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo

Hao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the most common malignant tumors in the urinary system with growing morbidity and diagnostic rate in recent years. Therefore, identifying new molecular biomarkers that inhibit the progression of bladder cancer is needed for developing further therapeutics. This study found a new potential treatment target: vaccinia-related kinase 1 (VRK1) and explored the function and mechanism of VRK1 in the development of bladder cancer. First, TCGA database and tissue microarray analysis showed that VRK1 was significantly upregulated in bladder cancer. Kaplan–Meier survival analysis indicates that the OS and PFS of the VRK1 high expression group were significantly lower than the VRK1 low expression group (p = 0.002, p = 0.005). Cox multi-factor analysis results show that VRK1 expression is an independent risk factor affecting tumor progress. The maximum tumor diameter, staging, and adjuvant chemotherapy also have a certain impact on tumor progression (p < 0.05). In internal validation, the column C index is 0.841 (95% CI, 0.803–0.880). In addition, cell functional studies have shown that VRK1 can significantly inhibit the proliferation, migration, and invasiveness of bladder cancer cells. In vivo, nude mice transplanted tumors further prove that low VRK1 can significantly inhibit the proliferation capacity of bladder cancer cells. In summary, VRK1 expression is significantly related to the staging, grade, and poor prognosis of patients with bladder cancer. At the same time, in vivo and in vitro experiments have shown that downregulation of VRK1 can significantly inhibit the proliferation of bladder cancer cells. These findings provide a basis for using VRK1 as a potential therapeutic target for patients with bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo

Hao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Based on a risk score model, AC010894.3 was included in a four-lncRNA signature that accurately predicted the OS of OC patients, and its increased expression was associated with better survival [ 62 ]. Three other lncRNAs from our gene list, AC244502.1 , AP002807.1 , and AP002518.2 , were integrated into prognostic signatures for breast cancer, clear cell renal cell carcinoma, and Wilms tumor, respectively [ 65 , 66 , 67 ]. The lncRNA SNHG12 was selected as a candidate due to its inverse correlation between high expression levels and DNA hypomethylation in carboplatin-resistant OC cell lines.…”

Section: Discussionmentioning

confidence: 99%

The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms

Abildgaard

Canto

Rainho

et al. 2022

Cancers

View full text Add to dashboard Cite

Genetic and epigenetic changes contribute to intratumor heterogeneity and chemotherapy resistance in several tumor types. LncRNAs have been implicated, directly or indirectly, in the epigenetic regulation of gene expression. We investigated lncRNAs that potentially mediate carboplatin-resistance of cell subpopulations, influencing the progression of ovarian cancer (OC). Four carboplatin-sensitive OC cell lines (IGROV1, OVCAR3, OVCAR4, and OVCAR5), their derivative resistant cells, and two inherently carboplatin-resistant cell lines (OVCAR8 and Ovc316) were subjected to RNA sequencing and global DNA methylation analysis. Integrative and cross-validation analyses were performed using external (The Cancer Genome Atlas, TCGA dataset, n = 111 OC samples) and internal datasets (n = 39 OC samples) to identify lncRNA candidates. A total of 4255 differentially expressed genes (DEGs) and 14529 differentially methylated CpG positions (DMPs) were identified comparing sensitive and resistant OC cell lines. The comparison of DEGs between OC cell lines and TCGA-OC dataset revealed 570 genes, including 50 lncRNAs, associated with carboplatin resistance. Eleven lncRNAs showed DMPs, including the SNHG12. Knockdown of SNHG12 in Ovc316 and OVCAR8 cells increased their sensitivity to carboplatin. The results suggest that the lncRNA SNHG12 contributes to carboplatin resistance in OC and is a potential therapeutic target. We demonstrated that SNHG12 is functionally related to epigenetic mechanisms.

show abstract

“…Gong et al found that the established ceRNA network was closely related in the progression and metastasis of ccRCC and 3 lncRNAs that may be related to ccRCC prognosis [ 21 ]. However, the difference or advantage of our study lies in a more accurate survival-related ceRNA network [ 22 , 23 ]. Among DERNAs, the total 2,307 DEmRNAs (761 downregulated and 1,546 upregulated), 54 DEmiRNAs (21 downregulated and 33 upregulated), and 1,456 DElncRNAs (459 downregulated and 997 upregulated) were screened.…”

Section: Discussionmentioning

confidence: 99%

A ceRNA Network Composed of Survival-Related lncRNAs, miRNAs, and mRNAs in Clear Cell Renal Carcinoma

Liu

Zhang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Clear cell renal carcinoma (ccRCC) is one of the most common renal carcinomas worldwide, which has worse prognosis compared with other subtypes of tumors. We propose a potential RNA regulatory mechanism associated with ccRCC progression. Accordingly, we screened out clinical factors and the expression of RNAs and miRNAs of ccRCC from the TCGA database. 9 lncRNAs (FGF12-AS2, WT1-AS, TRIM36-IT1, AC009093.1, LINC00443, TCL6, COL18A1-AS1, AC110619.1, HOTTIP), 2 miRNAs (mir-155 and mir-21), and 3 mRNAs (COL4A4, ERMP1, PRELID2) were selected from differential expression RNAs and built predictive survival models. The survival models performed very well in predicting prognosis and were found to be highly correlated with tumor stage. In addition, the survival-related lncRNA-miRNA-mRNA (ceRNA) network was constructed by 18 RNAs including 12 mRNAs, 2 miRNAs, and 4 lncRNAs. It is found that the “ECM-receptor interaction,” “Pathways in cancer,” and “Chemokine signaling pathway” as the main pathways in KEGG pathway analysis. Overall, we established predictive survival model and ceRNA network based on multivariate Cox regression analysis. It may open a new approach and potential biomarkers for clinical prognosis and treatment of ccRCC patients.

show abstract

A Survival-Related Competitive Endogenous RNA Network of Prognostic lncRNAs, miRNAs, and mRNAs in Wilms Tumor

Cited by 8 publications

References 41 publications

VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo

VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo

The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms

A ceRNA Network Composed of Survival-Related lncRNAs, miRNAs, and mRNAs in Clear Cell Renal Carcinoma

Contact Info

Product

Resources

About